Metastatic Prostate Cancer
Conditions
Keywords
metastatic prostate cancer, next-generation sequencing
Brief summary
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.
Detailed description
Next-generation sequencing is recommended by national guidelines in metastatic prostate cancer to inform prognosis, treatment decisions, and eligibility for clinical trials. However, rates are low nationally and around 50-60% at Johns Hopkins. Analysis found that older patients and patients who are not married are less likely to have testing performed. The goals and objectives of this proposed clinical trial are to improve NGS testing rates at Johns Hopkins using a multidisciplinary approach to improve the care of patients living with metastatic prostate cancer and reduce disparities. The hypothesis is that this initiative, which targets two barriers (provider-level and patient-level), will lead to higher rates of NGS ordering at Johns Hopkins.
Interventions
OTHERProvider-level and patient education at end of study
The provider level component will involve an email to each of the genitourinary medical oncologists at Johns Hopkins with their NGS testing rate from preliminary data and compare this rate to the mean. The initial email will also include the 2025 ASCO guideline recommending somatic testing in virtually all metastatic prostate cancer patients. Providers who do not have baseline NGS testing rates available will also be emailed. Providers will subsequently be emailed their updated NGS testing rate at the conclusion of the study period. Patients will also receive a one-page patient educational material (via email, or mail if no email on file) on advanced prostate cancer that includes education on somatic NGS testing at the end of the study period.
OTHERProvider-level and patient-level
In addition to the provider component, patients will also receive a one-page patient educational material (via email, or mail if no email on file) on advanced prostate cancer that includes education on somatic NGS testing. The email will be sent by the MyChart Recruitment Innovation team. Those without email on file will have the same message and attachment sent via mail by our study coordinator.
Sponsors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* men diagnosed with metastatic prostate cancer * seen by Johns Hopkins Medical Oncology as a new patient visit between January 1, 2025 and December 31, 2026
Exclusion criteria
\- Patients who have already had NGS testing performed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of Next-Generation Sequencing (NGS) testing by arm | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of patients with sociodemographic and clinical characteristics who have had NGS testing compared to those without NGS testing during the study period. | 1 year |
Countries
United States
Contacts
CONTACTCatherine Marshall, MD
CONTACTMaddie Klugman
PRINCIPAL_INVESTIGATORCatherine Marshall, MD
Johns Hopkins University
Outcome results
None listed